RxDoctor Payments DataLook up a doctor →

Miguel Valderrabano, MD

Clinical Cardiac Electrophysiology · Houston, TXNPI 1851334908

Payments from drug & device makers

$1,339,405in general payments, 2019–2025

Across 1,598 payments — averaging $838.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$443K
  • Medical Device Business Services, Inc.$329K
  • Biosense Webster, Inc.$230K
  • Medtronic$101K
  • Circa Scientific, Inc.$92K
  • Boston Scientific$40K
  • plus $105K from 28 others

What the payments were for

  • Consulting fees$323,49970%
  • Speaking & faculty fees$55,31312%
  • Travel & lodging$43,3249%
  • Food & beverage$38,4428%
  • Education$3050%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,339,405 in reported general payments places this provider in the 95th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$259,978
Medicare patients
357
Services billed
1,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$234,489
XareltoRivaroxaban59$84,811
MultaqDronedarone Hcl21$34,316
Propafenone Hcl ErPropafenone Hcl26$6,698
Flecainide Acetate48$3,073
Metoprolol Succinate106$2,433
Amiodarone Hcl54$1,512
Propafenone Hcl14$1,312
Metoprolol Tartrate61$616
SotalolSotalol Hcl20$485
Atorvastatin Calcium41$428
Carvedilol25$313
Digoxin13$301
Ramipril22$245
Potassium Chloride15$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$234,489181 claims
Johnson & JohnsonXarelto$96$84,81159 claims
Sanofi-aventis U.S. LLCMultaq$52$34,31621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →